Target General Information
Target ID T56365 Target Info
Target Name B-lymphocyte surface antigen B4 (CD19)
Synonyms T-cell surface antigen Leu-12; Leu-12; Differentiation antigen CD19; B-lymphocyte antigen CD19
Target Type Successful Target
Gene Name CD19
Biochemical Class Immunoglobulin
UniProt ID
Targeted Antigens of CAR-T Cell Therapy
CAR T-Cell Therapy Drug(s) Axicabtagene ciloleucel Drug Info Approved Diffuse large B-cell lymphoma [1]
Tisagenlecleucel Drug Info Approved Acute lymphoblastic leukaemia [1]
Axicabtagene ciloleucel Drug Info Phase 2/3 Primary mediastinal B-cell lymphoma [2], [2], [3]
CART-19 Drug Info Phase 2/3 Acute lymphoblastic leukaemia [4]
CD19 CAR T cells Drug Info Phase 2/3 B-cell lymphoma [5], [6]
Axicabtagene ciloleucel Drug Info Phase 2 Non-hodgkin lymphoma [3]
CAR-T cells targeting CD19 Drug Info Phase 2 Non-hodgkin lymphoma [7]
CART 19 Drug Info Phase 2 Acute lymphoblastic leukaemia [8], [9]
CART-19 Drug Info Phase 2 Non-hodgkin lymphoma [10], [11], [12], [13]
CART-19 cells Drug Info Phase 2 Multiple myeloma [14]
CD19 CAR T cells Drug Info Phase 2 Non-hodgkin lymphoma [15]
CD19-targeting CAR T cells Drug Info Phase 2 leukaemia [16], [17]
CTL019 Drug Info Phase 2 Diffuse large B-cell lymphoma [18], [19]
JCAR015 Drug Info Phase 2 Acute lymphoblastic leukaemia [20]
JCAR017 Drug Info Phase 2 Richter syndrome [21], [21], [22], [22], [23]
KYMRIAH Drug Info Phase 2 Acute lymphoblastic leukaemia [24]
MB-CART19.1 Drug Info Phase 2 Precursor B-lymphoblastic neoplasm [25]
Tisagenlecleucel Drug Info Phase 2 Diffuse large B-cell lymphoma [26], [2]
XLCART001 Drug Info Phase 2 B-cell lymphoma [27]
YESCARTA Drug Info Phase 2 Diffuse large B-cell lymphoma [24]
4SCAR19 and 4SCAR123 Drug Info Phase 1/2 B-cell lymphoma [28]
4SCAR19 and 4SCAR20 Drug Info Phase 1/2 B-cell lymphoma [28]
4SCAR19 and 4SCAR22 Drug Info Phase 1/2 B-cell lymphoma [28]
4SCAR19 and 4SCAR30 Drug Info Phase 1/2 B-cell lymphoma [28]
4SCAR19 and 4SCAR38 Drug Info Phase 1/2 B-cell lymphoma [28]
4SCAR19 and 4SCAR70 Drug Info Phase 1/2 B-cell lymphoma [28]
4SCAR19 cells Drug Info Phase 1/2 B-cell lymphoma [29]
4SCAR19/22 T cells Drug Info Phase 1/2 leukaemia [30]
Anti-CD19 and Anti-CD20 CAR-T Cells Drug Info Phase 1/2 B-cell lymphoma [31]
Anti-CD19 CAR T cells Drug Info Phase 1/2 B-cell lymphoma [32], [33]
Anti-CD19 CAR transduced T cells Drug Info Phase 1/2 Lymphoma [34]
Anti-CD19 CAR-T Drug Info Phase 1/2 Haematopoietic/lymphoid cancer [35]
Anti-CD19 CAR-T cells Drug Info Phase 1/2 Mantle cell lymphoma [36]
Anti-CD19 CAR-T cells Drug Info Phase 1/2 B-cell chronic lymphocytic leukaemia [37]
Anti-CD19 CAR-T cells Drug Info Phase 1/2 Lymphoma [38]
Anti-CD19 CAR-T cells Drug Info Phase 1/2 B-cell lymphoma [39], [40]
Anti-CD19-CAR PBL Drug Info Phase 1/2 Primary mediastinal B-cell lymphoma [41]
Anti-CD19-CAR vector-transduced T cells Drug Info Phase 1/2 Mantle cell lymphoma [42], [43]
Anti-CD19-CAR-T cells Drug Info Phase 1/2 leukaemia [44]
Anti-CD19/22-CAR vector-transduced T cells Drug Info Phase 1/2 Prolymphocytic leukaemia [45]
Anti-CD20 CAR-T cells Drug Info Phase 1/2 Diffuse large B-cell lymphoma [46]
AUTO3 Drug Info Phase 1/2 Diffuse large B-cell lymphoma [47], [48]
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes Drug Info Phase 1/2 Non-hodgkin lymphoma [49]
Autologous CD19-targeting CAR T cells Drug Info Phase 1/2 leukaemia [50]
CAR-T cells targeting CD19 Drug Info Phase 1/2 Multiple myeloma [51]
CARCIK-CD19 Drug Info Phase 1/2 Acute lymphocytic leukaemia [52]
CART-19 cells Drug Info Phase 1/2 Acute lymphoblastic leukaemia [53]
CART-19/22 Drug Info Phase 1/2 leukaemia [54]
CART-19/BCMA Drug Info Phase 1/2 Multiple myeloma [55]
CD19 and CD20 CAR-T Cells Drug Info Phase 1/2 leukaemia [56]
CD19 and CD22 CAR-T Cells Drug Info Phase 1/2 leukaemia [56]
CD19 and CD22 CAR-T Cells Drug Info Phase 1/2 Lymphoma [57]
CD19 CAR Gene Transduced T Lymphocytes Drug Info Phase 1/2 Non-hodgkin lymphoma [58]
CD19 CAR T cells Drug Info Phase 1/2 B-cell non-hodgkin lymphoma [59]
CD19 CAR T Cells Drug Info Phase 1/2 Mantle cell lymphoma [60]
CD19 CAR-T Cells Drug Info Phase 1/2 Acute lymphoblastic leukaemia [61]
CD19 CAR-T lymphocytes Drug Info Phase 1/2 Acute lymphoblastic leukaemia [62]
CD19 CART Drug Info Phase 1/2 B-cell lymphoma [63]
CD19 CART Drug Info Phase 1/2 Acute lymphoblastic leukaemia [64]
CD19 specific CAR T cells Drug Info Phase 1/2 Acute leukaemia [65]
CD19 targeted chimeric antigen receptor T cells Drug Info Phase 1/2 B-cell lymphoma [66]
CD19-CAR T cell Drug Info Phase 1/2 Non-hodgkin lymphoma [67]
CD19-directed CAR-T cells Drug Info Phase 1/2 Lymphoma [68]
CD19-targeting CAR T Cells Drug Info Phase 1/2 B-cell lymphoma [69]
CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells Drug Info Phase 1/2 Haematopoietic/lymphoid cancer [70]
CD19.CAR T Cells Drug Info Phase 1/2 Mantle cell lymphoma [71]
CD19.CAR-T cells Drug Info Phase 1/2 Mantle cell lymphoma [72]
Chimeric Antigen Receptor Modified T cells Targeting CD19 Drug Info Phase 1/2 Lymphoma [73]
CLIC-1901 Drug Info Phase 1/2 Non-hodgkin lymphoma [74]
Humanized CD19 CAR-T cells Drug Info Phase 1/2 Acute lymphoblastic leukaemia [75]
IM19 CAR-T Drug Info Phase 1/2 leukaemia [76], [77]
JCAR017 Drug Info Phase 1/2 Chronic lymphocytic leukaemia [78], [79]
JCAR017 Drug Info Phase 1/2 Precursor B-lymphoblastic neoplasm [23]
PBCAR0191 Drug Info Phase 1/2 Non-hodgkin lymphoma [80]
PCAR-019 (anti-CD19 CAR-T cells) Drug Info Phase 1/2 Mantle cell lymphoma [81]
SCRI-huCAR19v1 Drug Info Phase 1/2 Lymphoma [82]
SJCAR19 Drug Info Phase 1/2 Acute lymphoblastic leukaemia [83]
TBI-1501 Drug Info Phase 1/2 Acute lymphoblastic leukaemia [84]
TriCAR-T-CD19 Drug Info Phase 1/2 Non-hodgkin lymphoma [85]
UCART019 Drug Info Phase 1/2 leukaemia [86]
19-28z T CELLS Drug Info Phase 1 Non-hodgkin lymphoma [87]
4SCAR19 cells Drug Info Phase 1 Acute lymphoblastic leukaemia [88]
Allogeneic CART-19 Drug Info Phase 1 leukaemia [89]
Anti-CD19 anti-CD20 Bispecific CAR-T Drug Info Phase 1 Lymphoma [90]
Anti-CD19 CAR-T Drug Info Phase 1 Haematopoietic/lymphoid cancer [91]
Anti-CD19 CAR-T cells Drug Info Phase 1 Lymphoma [92]
Anti-CD19 CART Cells Drug Info Phase 1 Multiple myeloma [93]
Anti-CD19- CAR Drug Info Phase 1 Non-hodgkin lymphoma [94]
Anti-CD19-CAR T Drug Info Phase 1 Lymphoma [95]
Anti-CD19-CAR T cells Drug Info Phase 1 Non-hodgkin lymphoma [96]
Anti-CD19/BCMA CAR-T cells Drug Info Phase 1 Multiple myeloma [97]
AntiCD19 CART Drug Info Phase 1 Non-hodgkin lymphoma [98]
ARI-0001 cells Drug Info Phase 1 Lymphoma [99]
Axicabtagene ciloleucel Drug Info Phase 1 Acute lymphoblastic leukaemia [2]
BCMA CART and huCART19 Drug Info Phase 1 Multiple myeloma [100]
C-CAR011 Drug Info Phase 1 Non-hodgkin lymphoma [101], [102]
CAR-20/19-T Cells Drug Info Phase 1 Pancreatic cancer [103]
CAR-T Cells targeting CD19 Drug Info Phase 1 Acute lymphoblastic leukaemia [104]
CAR-T cells targeting CD19 Drug Info Phase 1 Lymphoma [105]
CAR19 T cells carrying cytoplasmic activated PD-1 Drug Info Phase 1 Non-hodgkin lymphoma [106]
CART-19 Drug Info Phase 1 B-cell lymphoma [107]
CART-19 Drug Info Phase 1 Prolymphocytic leukaemia [108], [11]
CART-19 Drug Info Phase 1 Acute lymphoblastic leukaemia [109]
CART-19 autologous T-cells Drug Info Phase 1 Lymphoma [110]
CART-19 cells Drug Info Phase 1 Acute lymphoblastic leukaemia [111]
CART-19 cells Drug Info Phase 1 Acute lymphocytic leukaemia [112]
CART-19 cells Drug Info Phase 1 Acute lymphoblastic leukaemia [113]
CART-19 T cells Drug Info Phase 1 Multiple myeloma [114]
CART-meso-19 T cells Drug Info Phase 1 Pancreatic cancer [115]
CART19 cell Drug Info Phase 1 B-cell prolymphocytic leukaemia [116]
CART22-65s cells and huCART19 Cells Drug Info Phase 1 Acute lymphoblastic leukaemia [117]
CARTmeso/19 Drug Info Phase 1 Pancreatic cancer [118]
CD19 CAR T Drug Info Phase 1 B-cell lymphoma [119]
CD19 CAR T Cells Drug Info Phase 1 Non-hodgkin lymphoma [120]
CD19 CAR T cells Drug Info Phase 1 B-cell non-hodgkin lymphoma [121], [122]
CD19 CAR T-cells Drug Info Phase 1 Non-hodgkin lymphoma [123]
CD19 CAR T-cells Drug Info Phase 1 Recurrent adult burkitt lymphoma [124]
CD19 CAR-T cells Drug Info Phase 1 Acute lymphoblastic leukaemia [125]
CD19 CAR-T cells Drug Info Phase 1 Acute lymphoblastic leukaemia [126]
CD19 Redirected Autologous T Cells Drug Info Phase 1 Systemic lupus erythematosus [127]
CD19+ CAR T Cells Drug Info Phase 1 Lymphoma [128]
CD19-CAR and CD28-CAR T Cells Drug Info Phase 1 Acute lymphoblastic leukaemia [129]
CD19-CAR-T Cells Drug Info Phase 1 Acute lymphoblastic leukaemia [130]
CD19-CAR-T2 Cells Drug Info Phase 1 Acute lymphoblastic leukaemia [131]
CD19-directed CAR-T cells Drug Info Phase 1 leukaemia [132]
CD19-directed CAR-T cells Drug Info Phase 1 Non-hodgkin lymphoma [133]
CD19-targeted CART cells Drug Info Phase 1 leukaemia [134]
CD19-TriCAR-T Drug Info Phase 1 Non-hodgkin lymphoma [135]
CD19.CAR-aNKT cells Drug Info Phase 1 Non-hodgkin lymphoma [136]
CD19/CD22 CAR T cells Drug Info Phase 1 Acute lymphoblastic leukaemia [137]
CD19/CD22 CAR T-Cells Drug Info Phase 1 Non-hodgkin lymphoma [138]
CD19/CD22 Chimeric Antigen Receptor T Cells Drug Info Phase 1 Mediastinal large B-cell lymphoma [139]
CD19CAT-41BBZ CAR T-cells Drug Info Phase 1 Acute lymphoblastic leukaemia [140]
Donor-derived CD19/22 bispecific CAR-T cells Drug Info Phase 1 leukaemia [132]
Dual Specificity CD19 and CD22 CAR-T Cell Drug Info Phase 1 Lymphoma [141]
EGFRt/19-28z/4-1BBL CAR T cells Drug Info Phase 1 Chronic lymphocytic leukaemia [142]
HuCART19 Drug Info Phase 1 Lymphoma [143]
Human CD19 targeted T Cells Drug Info Phase 1 Follicular lymphoma [144]
IC9-CAR19 cells Drug Info Phase 1 Immunoproliferative disorder [145], [146]
IC9-CAR19 T cells Drug Info Phase 1 Lymphoma [147]
ICAR19 CAR-T cells Drug Info Phase 1 leukaemia [148]
IM19 Drug Info Phase 1 Non-hodgkin lymphoma [149], [150]
JCAR014 Drug Info Phase 1 Mediastinal large B-cell lymphoma [151]
JCAR017 Drug Info Phase 1 Primary mediastinal B-cell lymphoma [78], [152], [152], [78]
JWCAR029 Drug Info Phase 1 Non-hodgkin lymphoma [153]
JWCAR029 Drug Info Phase 1 Non-hodgkin lymphoma [154]
Patient-derived CD19- and CD22 specific CAR Drug Info Phase 1 Lymphoma [155]
PZ01 CAR-T cells Drug Info Phase 1 B-cell lymphoma [156]
Anti-CD19 Chimeric Antigen Receptor T Cells Drug Info Clinical trial leukaemia [157]
Anti-CD19-CAR vector-transduced T cells Drug Info Clinical trial Prolymphocytic leukaemia [43]
Anti-CD19/20-CAR vector-transduced T cells Drug Info Clinical trial Prolymphocytic leukaemia [158]
CAR-CD19 T cell Drug Info Clinical trial leukaemia [159]
CD19-CAR T Cells Drug Info Clinical trial Acute lymphoblastic leukaemia [160]
CD19-targeted CAR-T cells Drug Info Clinical trial leukaemia [161]
CD19-targeted CAR-T cells Drug Info Clinical trial Lymphoma [162], [163], [164]
CD19-UCART Drug Info Clinical trial Non-hodgkin lymphoma [165]
CD19CART Drug Info Clinical trial leukaemia [166]
CTL019 Drug Info Clinical trial Acute lymphoblastic leukaemia [19]
JCAR017 Drug Info Clinical trial Multiple myeloma [78]
Axicabtagene ciloleucel Drug Info Application submitted Non-hodgkin lymphoma [2]
Tisagenlecleucel Drug Info Application submitted Acute myeloid leukaemia [2]
Anti-CD19 CAR T cells Drug Info Phase 0 Hodgkin lymphoma [167]
CART19 cells Drug Info Phase 0 Hodgkin lymphoma [168]
CART 19 Drug Info Preclinical Pancreatic cancer [169]
References
REF 1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
REF 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 4 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
REF 5 ClinicalTrials.gov (NCT03391739) CART-19 Cells For R/R B-ALL
REF 6 ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
REF 7 ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
REF 8 ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
REF 9 ClinicalTrials.gov (NCT02906371) Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
REF 10 ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
REF 11 ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
REF 12 ClinicalTrials.gov (NCT02030847) Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
REF 13 ClinicalTrials.gov (NCT01747486) CD19 Redirected Autologous T Cells
REF 14 ClinicalTrials.gov (NCT02794246) CART-19 Post-ASCT for Multiple Myeloma
REF 15 ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
REF 16 ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
REF 17 ClinicalTrials.gov (NCT03068416) CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
REF 18 ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health.
REF 19 ClinicalTrials.gov (NCT03601442) CTL019 Out of Specification MAP for ALL or DLBCL Patients
REF 20 ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL).
REF 21 ClinicalTrials.gov (NCT03484702) Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
REF 22 ClinicalTrials.gov (NCT03310619) A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)
REF 23 ClinicalTrials.gov (NCT03743246) A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
REF 24 ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies
REF 25 ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL
REF 26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
REF 27 ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
REF 28 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
REF 29 ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
REF 30 ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
REF 31 ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
REF 32 ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
REF 33 ClinicalTrials.gov (NCT02247609) Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
REF 34 ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
REF 35 ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma
REF 36 ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
REF 37 ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy
REF 38 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
REF 39 ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
REF 40 ClinicalTrials.gov (NCT03366350) Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
REF 41 ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
REF 42 ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma
REF 43 ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
REF 44 ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
REF 45 ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
REF 46 ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)
REF 47 ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
REF 48 ClinicalTrials.gov (NCT03287817) CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
REF 49 ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
REF 50 ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy
REF 51 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
REF 52 ClinicalTrials.gov (NCT03389035) Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT
REF 53 ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL
REF 54 ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
REF 55 ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
REF 56 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
REF 57 ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
REF 58 ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
REF 59 ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
REF 60 ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
REF 61 ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
REF 62 ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
REF 63 ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
REF 64 ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL
REF 65 ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
REF 66 ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
REF 67 ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
REF 68 ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy
REF 69 ClinicalTrials.gov (NCT02547948) CD19-targeting CAR T Cells for B Cell Lymphoma
REF 70 ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy
REF 71 ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
REF 72 ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
REF 73 ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
REF 74 ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
REF 75 ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
REF 76 ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells
REF 77 ClinicalTrials.gov (NCT03173417) Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
REF 78 ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
REF 79 ClinicalTrials.gov (NCT03331198) Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
REF 80 ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
REF 81 ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
REF 82 ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
REF 83 ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
REF 84 ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
REF 85 ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
REF 86 ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
REF 87 ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
REF 88 ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
REF 89 ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL
REF 90 ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
REF 91 ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
REF 92 ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
REF 93 ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
REF 94 ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
REF 95 ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
REF 96 ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
REF 97 ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
REF 98 ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
REF 99 ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy
REF 100 ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
REF 101 ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL
REF 102 ClinicalTrials.gov (NCT03154775) Study of Safety and Efficacy of C-CAR011 in B-NHL Patients
REF 103 ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
REF 104 ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
REF 105 ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma
REF 106 ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
REF 107 ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma
REF 108 ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
REF 109 ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
REF 110 ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP
REF 111 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
REF 112 ClinicalTrials.gov (NCT01551043) Allo CART-19 Protocol
REF 113 ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
REF 114 ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma
REF 115 ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
REF 116 ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
REF 117 ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
REF 118 ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
REF 119 ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
REF 120 ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
REF 121 ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
REF 122 ClinicalTrials.gov (NCT03029338) CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
REF 123 ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
REF 124 ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
REF 125 ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
REF 126 ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
REF 127 ClinicalTrials.gov (NCT03030976) A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
REF 128 ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies
REF 129 ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
REF 130 ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL
REF 131 ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
REF 132 ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
REF 133 ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
REF 134 ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
REF 135 ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy
REF 136 ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
REF 137 ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
REF 138 ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
REF 139 ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
REF 140 ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19
REF 141 ClinicalTrials.gov (NCT03593109) Safety and Efficacy Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in Relapsed or Refractory Lymphoma
REF 142 ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
REF 143 ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
REF 144 ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
REF 145 ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
REF 146 ClinicalTrials.gov (NCT03594162) Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
REF 147 ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
REF 148 ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
REF 149 ClinicalTrials.gov (NCT03344705) Safety and Efficacy Evaluation of IM19 Cells
REF 150 ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
REF 151 ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
REF 152 ClinicalTrials.gov (NCT02631044) Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
REF 153 ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
REF 154 ClinicalTrials.gov (NCT03355859) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
REF 155 ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma
REF 156 ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
REF 157 ClinicalTrials.gov (NCT03624686) Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies
REF 158 ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
REF 159 ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
REF 160 ClinicalTrials.gov (NCT03423706) Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
REF 161 ClinicalTrials.gov (NCT03564977) CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
REF 162 ClinicalTrials.gov (NCT02735291) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia
REF 163 ClinicalTrials.gov (NCT02728882) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
REF 164 ClinicalTrials.gov (NCT03488160) CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma
REF 165 ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART
REF 166 ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies
REF 167 ClinicalTrials.gov (NCT02277522) CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
REF 168 ClinicalTrials.gov (NCT02624258) Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
REF 169 ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.